Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease

Experimental Neurology

Volumn 237, Issue 1, 2012, Pages 78-89

  Kumar, Ashish ^a   Kneynsberg, Andrew ^a   Tucholski, Janusz ^a   Perry, Giselle ^a   van Groen, Thomas ^b   Detloff, Peter J ^c   Lesort, Mathieu ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aggregates; Huntington's disease; Modifiers; Mouse model; Phenotype; Transglutaminase

Indexed keywords

PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOTYPE; GRIP STRENGTH; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOTOR COORDINATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; STEREOLOGY; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TRANSGENE; TRANSGENIC MOUSE; WEIGHT CHANGE;

AGE OF ONSET; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; RANDOM ALLOCATION; TRANSGLUTAMINASES;

EID: 84863839736     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.05.015     Document Type: Article

References (70)

1. Bailey C.D., Johnson G.V. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J. Neurochem. 2005, 92:83-92.
2. Bailey C.D., Johnson G.V. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol. Aging 2006, 27:871-879.
3. Beal M.F. Huntington's disease, energy, and excitotoxicity. Neurobiol. Aging 1994, 15:275-276.
4. Beal M.F. Mitochondria, free radicals, and neurodegeneration. Curr. Opin. Neurobiol. 1996, 6:661-666.
5. Bezprozvanny I., Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322:1310-1317.
6. Bousquet M., Gibrat C., Ouellet M., Rouillard C., Calon F., Cicchetti F. Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J. Neurochem. 2010, 114:1651-1658.
7. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 2001, 66:525-539.
8. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
9. Chun W., Lesort M., Tucholski J., Ross C.A., Johnson G.V. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J. Cell Biol. 2001, 153:25-34.
10. Cooper A.J., Sheu K.F., Burke J.R., Onodera O., Strittmatter W.J., Roses A.D., Blass J.P. Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?. J. Neurochem. 1997, 69:431-434.
11. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
12. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M., Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 2002, 22:8942-8950.
13. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A., et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
14. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
15. Fan M.M., Raymond L.A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
16. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
17. Filiano A.J., Bailey C.D., Tucholski J., Gundemir S., Johnson G.V. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J. 2008, 22:2662-2675.
18. Filiano A.J., Tucholski J., Dolan P.J., Colak G., Johnson G.V. Transglutaminase 2 protects against ischemic stroke. Neurobiol. Dis. 2010, 39:334-343.
19. Fischbeck K.H. Polyglutamine expansion neurodegenerative disease. Brain Res. Bull. 2001, 56:161-163.
20. Gentile V., Sepe C., Calvani M., Melone M.A., Cotrufo R., Cooper A.J., Blass J.P., Peluso G. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch. Biochem. Biophys. 1998, 352:314-321.
21. Green H. Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 1993, 74:955-956.
22. Greenberg C.S., Birckbichler P.J., Rice R.H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991, 5:3071-3077.
23. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
24. Hockly E., Woodman B., Mahal A., Lewis C.M., Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res. Bull. 2003, 61:469-479.
25. Iismaa S.E., Mearns B.M., Lorand L., Graham R.M. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol. Rev. 2009, 89:991-1023.
26. Jeitner T.M., Bogdanov M.B., Matson W.R., Daikhin Y., Yudkoff M., Folk J.E., Steinman L., Browne S.E., Beal M.F., Blass J.P., Cooper A.J. N(epsilon)-(gamma-l-glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. J. Neurochem. 2001, 79:1109-1112.
27. Jeitner T.M., Delikatny E.J., Ahlqvist J., Capper H., Cooper A.J. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 2005, 69:961-970.
28. Jeitner T.M., Matson W.R., Folk J.E., Blass J.P., Cooper A.J. Increased levels of gamma-glutamylamines in Huntington disease CSF. J. Neurochem. 2008, 106:37-44.
29. Jeitner T.M., Battaile K., Cooper A.J. gamma-Glutamylamines and neurodegenerative diseases. Amino Acids 2012, (online first, 9 March 2012).
30. Kahlem P., Terre C., Green H., Djian P. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14580-14585.
31. Kahlem P., Green H., Djian P. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell. 1998, 1:595-601.
32. Kahlem P., Green H., Djian P. Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion. Pathol. Biol. (Paris) 1998, 46:681-682.
33. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 2002, 8:143-149.
34. Kegel K.B., Kim M., Sapp E., McIntyre C., Castano J.G., Aronin N., DiFiglia M. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci. 2000, 20:7268-7278.
35. Kim S.Y., Marekov L., Bubber P., Browne S.E., Stavrovskaya I., Lee J., Steinert P.M., Blass J.P., Beal M.F., Gibson G.E., Cooper A.J. Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. Neurochem. Res. 2005, 30:1245-1255.
36. Lai T.S., Tucker T., Burke J.R., Strittmatter W.J., Greenberg C.S. Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J. Neurochem. 2004, 88:1253-1260.
37. Lesort M., Chun W., Johnson G.V., Ferrante R.J. Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 1999, 73:2018-2027.
38. Lesort M., Tucholski J., Miller M.L., Johnson G.V. Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog. Neurobiol. 2000, 61:439-463.
39. Lesort M., Tucholski J., Zhang J., Johnson G.V. Impaired mitochondrial function results in increased tissue transglutaminase activity in situ. J. Neurochem. 2000, 75:1951-1961.
40. Lesort M., Lee M., Tucholski J., Johnson G.V. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 2003, 278:3825-3830.
41. Lorand L., Conrad S.M. Transglutaminases. Mol. Cell. Biochem. 1984, 58:9-35.
42. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003, 4:140-156.
43. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
44. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11:1911-1926.
45. Luthi-Carter R., Strand A.D., Hanson S.A., Kooperberg C., Schilling G., La Spada A.R., Merry D.E., Young A.B., Ross C.A., Borchelt D.R., Olson J.M. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 2002, 11:1927-1937.
46. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
47. Marder K., Zhao H., Eberly S., Tanner C.M., Oakes D., Shoulson I., G. Huntington Study Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 2009, 73:385-392.
48. Mastroberardino P.G., Iannicola C., Nardacci R., Bernassola F., De Laurenzi V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L., Piacentini M. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 2002, 9:873-880.
49. McConoughey S.J., Basso M., Niatsetskaya Z.V., Sleiman S.F., Smirnova N.A., Langley B.C., Mahishi L., Cooper A.J., Antonyak M.A., Cerione R.A., Li B., Starkov A., Chaturvedi R.K., Beal M.F., Coppola G., Geschwind D.H., Ryu H., Xia L., Iismaa S.E., Pallos J., Pasternack R., Hils M., Fan J., Raymond L.A., Marsh J.L., Thompson L.M., Ratan R.R. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med. 2010, 2:349-370.
50. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L., Skepper J.N., Wight J.M. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
51. 2max in females using aerobic dance, heart rate, BMI, and age. J. Sports Med. Phys. Fitness 1995, 35:159-168.
52. Panov A., Obertone T., Bennett-Desmelik J., Greenamyre J.T. Ca(2+)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease. Ann. N. Y. Acad. Sci. 1999, 893:365-368.
53. Perry T.L., Wright J.M., Hansen S., Thomas S.M., Allan B.M., Baird P.A., Diewold P.A. A double-blind clinical trial of isoniazid in Huntington disease. Neurology 1982, 32:354-358.
54. Perry G.M., Tallaksen-Greene S., Kumar A., Heng M.Y., Kneynsberg A., van Groen T., Detloff P.J., Albin R.L., Lesort M. Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease. Hum. Mol. Genet. 2010, 19:3354-3371.
55. Pinto J.T., Van Raamsdonk J.M., Leavitt B.R., Hayden M.R., Jeitner T.M., Thaler H.T., Krasnikov B.F., Cooper A.J. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J. Neurochem. 2005, 94:1087-1101.
56. Roos R.A. Huntington's disease: a clinical review. Orphanet J. Rare Dis. 2010, 5:40.
57. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
58. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
59. Rosas H.D., Feigin A.S., Hersch S.M. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx 2004, 1:263-272.
60. Rosas H.D., Lee S.Y., Bender A.C., Zaleta A.K., Vangel M., Yu P., Fischl B., Pappu V., Onorato C., Cha J.H., Salat D.H., Hersch S.M. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". NeuroImage 2010, 49:2995-3004.
61. Rossin F., D'Eletto M., Macdonald D., Farrace M.G., Piacentini M. TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy. Amino Acids 2012, 42(5):1793-1802.
62. Tallaksen-Greene S.J., Janiszewska A., Benton K., Ruprecht L., Albin R.L. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp. Neurol. 2010, 225:402-407.
63. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
64. Trushina E., Dyer R.B., Badger J.D., Ure D., Eide L., Tran D.D., Vrieze B.T., Legendre-Guillemin V., McPherson P.S., Mandavilli B.S., Van Houten B., Zeitlin S., McNiven M., Aebersold R., Hayden M., Parisi J.E., Seeberg E., Dragatsis I., Doyle K., Bender A., Chacko C., McMurray C.T. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 2004, 24:8195-8209.
65. Tucholski J., Roth K.A., Johnson G.V. Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. J. Neurochem. 2006, 97:582-594.
66. Van Raamsdonk J.M., Pearson J., Bailey C.D., Rogers D.A., Johnson G.V., Hayden M.R., Leavitt B.R. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J. Neurochem. 2005, 95:210-220.
67. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
68. Young A.B., Greenamyre J.T., Hollingsworth Z., Albin R., D'Amato C., Shoulson I., Penney J.B. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988, 241:981-983.
69. Zhang J., Lesort M., Guttmann R.P., Johnson G.V. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 1998, 273:2288-2295.
70. Zhang J., Tucholski J., Lesort M., Jope R.S., Johnson G.V. Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling. Biochem. J. 1999, 343(Pt 3):541-549.